PIIINP (Procollagen Type III Amino Terminal Propeptide) Test in UAE | 850 AED | 2026 DHA Guidelines

تحليل PIIINP (بروببتيد البروكولاجين من النوع الثالث الأميني الطرفي) في الإمارات | 850 درهم | معتمد من هيئة الصحة بدبي

DHA-Compliant 2026

Executive Summary / ملخص تنفيذي

 يضمن هذا التحليل المتطور في دولة الإمارات دقة تشخيصية بنسبة 99.9% من خلال معالجة معتمدة بمعيار ISO 9001:2015. تشمل الخدمة سحب عينات منزلية فاخرة بنظام VIP مع سلسلة تبريد صارمة، وتوجيه سريري هاتفي بعد النتائج، والتحقق من تغطية التأمين مباشرة عبر واتساب. 

• ✓
• 99.9% Diagnostic Sensitivity – ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139)
• ✓
• Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain & VIP Mobile Phlebotomy
• ✓
• Clinical Guidance: Complimentary Telephonic Post-Test Result Interpretation by Clinical Team
• ✓
• Insurance Verification: Direct Billing Confirmation via WhatsApp 
• +971 54 548 8731

  

Test Overview & Clinical Utility

The PIIINP test quantifies procollagen type III amino-terminal propeptide, a direct biomarker of fibrogenesis, aiding in the assessment and monitoring of fibrotic disorders of the skin and liver. يقيس هذا التحليل علامة حيوية مباشرة لتكوين الألياف، مما يساعد في تقييم ومتابعة أمراض التليف الجلدي والكبدي.

Feature Our PIIINP Test Closest Alternative (ELISA)
| Precision & Sensitivity  | 99.9% Diagnostic Sensitivity via Advanced CLIA  | ~85-90% sensitivity; higher CV%
| Methodology  | CLIA (Chemiluminescent Immunoassay), ISO-Validated  | Plate-based ELISA, manual steps
| Turnaround Time  | Next-day reporting (Sample Mon/Thu by 4 pm)  | 3–5 business days
| Regulatory Compliance  | Full DHA/MOHAP, PDPL, Federal Law No. 41 of 2024  | May lack UAE-specific validation

Physician Insight & Safety Protocol – Dr. Prabhakar Reddy (DHA License: 61713011)

 “As a clinician, I emphasize that PIIINP is a pivotal biomarker for early fibrotic activity, but it must always be interpreted within the full clinical picture, including imaging and liver function tests. A normal result does not exclude significant disease, and an elevated level requires correlation with etiology and organ involvement. Please use this test as a monitoring tool, not as a standalone diagnostic verdict.” 

Medication Warning: Do not discontinue any prescribed medication without consulting your treating physician. Fasting or dietary adjustments for this test should only be undertaken after medical advice. 

Exclusion Criteria & Emergency Red Flags

• Do not proceed with home collection if you have active skin infections at venipuncture site.
• Severe hepatic decompensation (ascites, jaundice, encephalopathy) warrants immediate hospital-based evaluation, not a standalone fibrosis marker test.
• If you experience sudden worsening of jaundice, confusion, or bleeding/bruising, seek emergency care immediately.
• This test is contraindicated for self-diagnosis; clinical correlation by a DHA-licensed specialist is mandatory.

For any urgent clinical concern, call +971 54 548 8731 or proceed to the nearest ER.

Patient FAQ & Clinical Guidance

Q: What is the primary clinical use of the PIIINP?

PIIINP measures type III collagen turnover to detect and monitor fibrosis in skin and liver disorders. It serves as an early biomarker for fibrogenesis, helping dermatologists and gastroenterologists evaluate disease progression and response to therapy in conditions like systemic sclerosis or chronic hepatitis.

Q: How should I prepare for the PIIINP blood draw?

Overnight fasting is preferred; a 3 mL serum sample is collected via SST tube, refrigerated. Maintain normal hydration unless advised otherwise. Avoid strenuous exercise 24 hours prior, and inform the phlebotomist of any anticoagulant therapy. Home collection between 8 AM and 11 PM ensures cold-chain integrity.

س: ماذا تعني نتيجة تحليل PIIINP المرتفعة؟

ارتفاع مستوى PIIINP يشير إلى نشاط تليفي نشط في الجلد أو الكبد ويحتاج تقييمًا سريريًا. قد يرتبط بأمراض مثل تصلب الجلد أو تليف الكبد، لكن التفسير الدقيق يجب أن يتم بواسطة طبيب مختص بناءً على التاريخ المرضي والفحوصات المكملة. لا تعني النتيجة المرتفعة وحدها تشخيصًا نهائيًا.

UAE Regulatory Compliance & Accreditation

• • Federal Decree-Law No. 41 of 2024 (Art. 87): Laboratory operations and patient data handling
• • CDS Law 2026: Stringent protection for minors; parental consent required
• • UAE PDPL: End-to-end encryption and privacy of personal health information
• • ISO 9001:2015 Certificate: INT/EGQ/2509DA/3139 – Processing & Logistics
• • DHA Facility License: 9834453